EUVIMEDEUVIMED entdecken
Open Access

Assessment of circulating biomarkers for detection of lung cancer in a high-risk cohort

Morten Borg, Line Nederby, Sara Witting Christensen Wen, Torben Frøstrup Hansen, Anders Jakobsen, Rikke Fredslund Andersen, Ulla Møller Weinreich, Ole Hilberg

Cancer Biomarkers · 20.01.2023 · 36 (1) · 63-69

DOI: 10.3233/cbm-210543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biomarkers, erschienen am 20.01.2023. Verfasst von Morten Borg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Diseases, Aalborg University Hospital, Aalborg, Denmark. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There is an urgent need for early detection of lung cancer. Screening with low-dose computed tomography (LDCT) is now implemented in the US. Supplementary use of a lung cancer biomarker with high specificity is desirable. OBJECTIVE: To assess the diagnostic properties of a biomarker panel consisting of cytokeratin 19 fragment (CYFRA 21-1), carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125). METHODS: A cohort of 250 high-risk patients was investigated on suspicion of lung cancer. Ahead of diagnostic work-up, blood samples taken. Cross-validated prediction models were computed to assess lung cancer detection properties. RESULTS: In total 32% (79/250) of patients were diagnosed with lung cancer. Area under the curve (AUC) for the three biomarkers was of 0.795, with sensitivity/specificity of 57%/93% and negative predictive value of 83%. When combining the biomarkers with US screening criteria, the AUC was 0.809, while applying only US screening criteria on the cohort, yielded an AUC of 0.62. The ability of the biomarkers to detect stage I-II lung cancer was substantially lower; AUC 0.54. CONCLUSIONS: In a high-risk cohort, the detection properties of the three biomarkers were acceptable compared to current LDCT screening criteria. However, the ability to detect early stage lung cancer was low.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHumansKeratin-19Biomarkers, TumorArea Under CurveCarcinoembryonic AntigenAntigens, Neoplasm

Stichwörter der Autor:innen

Lung cancerbiomarkerscancer antigen 125 (CA125)carcinoembryonic antigen (CEA)cytokeratin 19 fragment (CYFRA 21-1)screening

Substanzen

antigen CYFRA21.1Keratin-19Biomarkers, TumorCarcinoembryonic AntigenAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Respiratory Diseases, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Department of Internal Medicine, Lillebaelt Hospital, Vejle, Denmark.
  • Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, Denmark.
  • Department of Oncology, Lillebaelt Hospital, Vejle, Denmark.
  • Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.

Zitieren

APA

Borg, M., Nederby, L., Wen, S. W. C., Hansen, T. F., Jakobsen, A., Andersen, R. F., Weinreich, U. M., & Hilberg, O. (2023). Assessment of circulating biomarkers for detection of lung cancer in a high-risk cohort. Cancer Biomarkers, 36(1), 63-69. https://doi.org/10.3233/cbm-210543

Vancouver

Borg M, Nederby L, Wen SWC, Hansen TF, Jakobsen A, Andersen RF, et al. Assessment of circulating biomarkers for detection of lung cancer in a high-risk cohort. Cancer Biomarkers. 2023;36(1):63-69. doi:10.3233/cbm-210543

BibTeX
@article{Borg2023,
  author = {Borg, Morten and Nederby, Line and Wen, Sara Witting Christensen and Hansen, Torben Frøstrup and Jakobsen, Anders and Andersen, Rikke Fredslund and Weinreich, Ulla Møller and Hilberg, Ole},
  title = {Assessment of circulating biomarkers for detection of lung cancer in a high-risk cohort},
  journal = {Cancer Biomarkers},
  year = {2023},
  volume = {36},
  number = {1},
  pages = {63--69},
  doi = {10.3233/cbm-210543}
}
Kostenlos starten →